NASDAQ:BFRI Biofrontera (BFRI) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free BFRI Stock Alerts $1.26 -0.29 (-18.71%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$1.20▼$1.6950-Day Range$0.68▼$2.4552-Week Range$0.61▼$13.48Volume182,062 shsAverage Volume904,056 shsMarket Capitalization$6.41 millionP/E RatioN/ADividend YieldN/APrice Target$18.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Biofrontera alerts: Email Address Biofrontera MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,328.6% Upside$18.00 Price TargetShort InterestHealthy10.71% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.10Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.42 out of 5 stars 3.5 Analyst's Opinion Consensus RatingBiofrontera has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.00, Biofrontera has a forecasted upside of 1,328.6% from its current price of $1.26.Amount of Analyst CoverageBiofrontera has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted10.71% of the float of Biofrontera has been sold short.Short Interest Ratio / Days to CoverBiofrontera has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biofrontera has recently decreased by 59.01%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBiofrontera does not currently pay a dividend.Dividend GrowthBiofrontera does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BFRI. Previous Next 2.3 News and Social Media Coverage News SentimentBiofrontera has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Biofrontera this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for BFRI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows4 people have added Biofrontera to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biofrontera insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.69% of the stock of Biofrontera is held by insiders.Percentage Held by Institutions58.40% of the stock of Biofrontera is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Biofrontera is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biofrontera is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiofrontera has a P/B Ratio of 0.07. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm Press8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here: Click to get the name of the cryptocurrency About Biofrontera Stock (NASDAQ:BFRI)Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Read More BFRI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BFRI Stock News HeadlinesMarch 18, 2024 | msn.comBiofrontera GAAP EPS of $1.65 beats by $2.79, revenue of $10.6M misses by $1.21MFebruary 20, 2024 | msn.comBiofrontera stock soars on announcing private placement of up to $16MMarch 18, 2024 | Porter & Company (Ad)My next big prediction isn’t a predictionI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.February 20, 2024 | finance.yahoo.comBiofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AGJanuary 31, 2024 | finance.yahoo.comBiofrontera Inc. (NASDAQ:BFRI): Is Breakeven Near?January 11, 2024 | msn.comBiofrontera sees 19% growth in prelim FY 2023 revenueNovember 22, 2023 | finance.yahoo.comBiofrontera Inc. (BFRI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?November 11, 2023 | finance.yahoo.comBiofrontera Inc. (NASDAQ:BFRI) Q3 2023 Earnings Call TranscriptMarch 18, 2024 | Paradigm Press (Ad)8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here: November 11, 2023 | finance.yahoo.comBenign Growth For Biofrontera Inc. (NASDAQ:BFRI) Underpins Stock's 50% PlummetNovember 9, 2023 | finance.yahoo.comBiofrontera Inc. Reports Third Quarter 2023 Financial Results and Provides a Business UpdateNovember 9, 2023 | finance.yahoo.comBiofrontera Inc. (BFRI) Upgraded to Buy: Here's What You Should KnowNovember 3, 2023 | finance.yahoo.comBiofrontera Inc. to Report Third Quarter 2023 Financial Results on November 9 and Hold Conference Call on November 10October 31, 2023 | finance.yahoo.comBiofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ RulesOctober 21, 2023 | ca.finance.yahoo.comBiofrontera Inc. (BFRI) Stock Price, News, Quote & History - Yahoo FinanceOctober 10, 2023 | finanznachrichten.deBiofrontera Inc. Receives FDA Approval for New Formulation of AmeluzOctober 10, 2023 | finance.yahoo.comBiofrontera Inc. Receives FDA Approval for New Formulation of Ameluz(R)October 5, 2023 | finance.yahoo.comBiofrontera Inc. to Participate in the Roth MKM 2023 Healthcare Opportunities Conference and the 43rd Annual Fall Clinical Dermatology ConferenceSeptember 18, 2023 | msn.comAll You Need to Know About Biofrontera Inc. (BFRI) Rating Upgrade to BuyAugust 28, 2023 | finanznachrichten.deBiofrontera Inc. Announces Positive Results from Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of AmeluzAugust 28, 2023 | finance.yahoo.comBiofrontera Inc. Announces Positive Results from Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz(R)August 10, 2023 | benzinga.comEarnings Outlook For BiofronteraAugust 4, 2023 | finance.yahoo.comBiofrontera Inc. to Report Second Quarter Financial Results on August 11, 2023July 13, 2023 | finance.yahoo.comBiofrontera Inc. Announces Preliminary Second Quarter Revenues are Up 26% to 31%July 12, 2023 | finance.yahoo.comBiofrontera Inc. Appoints Dr. Heikki Lanckriet to its Board of DirectorsJune 1, 2023 | finanznachrichten.deBiofrontera Inc. Begins Development of a Portable Photodynamic Therapy Lamp for Use with Ameluz-PDTMay 30, 2023 | finance.yahoo.comBiofrontera Inc. Names Founder and Executive Chairman Hermann Luebbert as Chief Executive OfficerSee More Headlines Receive BFRI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biofrontera and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2023Today3/18/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BFRI CUSIPN/A CIK1858685 Webwww.biofrontera-us.com Phone781-245-1325FaxN/AEmployees81Year FoundedN/APrice Target and Rating Average Stock Price Target$18.00 High Stock Price Target$18.00 Low Stock Price Target$18.00 Potential Upside/Downside+1,117.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($20.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-640,000.00 Net Margins-78.65% Pretax Margin-78.58% Return on Equity-192.05% Return on Assets-57.24% Debt Debt-to-Equity RatioN/A Current Ratio1.02 Quick Ratio0.47 Sales & Book Value Annual Sales$28.67 million Price / Sales0.08 Cash FlowN/A Price / Cash FlowN/A Book Value$17.89 per share Price / Book0.08Miscellaneous Outstanding Shares1,520,000Free Float1,508,000Market Cap$2.25 million OptionableNo Data Beta0.54 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Hermann Luebbert Ph.D. (Age 68)CEO, President & Executive Chairman Comp: $733.23kMr. Eugene Frederick Leffler III (Age 39)Chief Financial Officer Comp: $378.58kMs. Erica F. Gates CPAM.B.A., Senior Director of Finance & Principal Accounting OfficerMr. Jon Lyons M.B.A.Ph.D., Vice President of Scientific & Medical AffairsMs. Alycia TorresVice President of AdministrationMr. Daniel Hakansson J.D.General Counsel & Head of ComplianceMs. Samantha WiddicombeSenior Director of Strategic Accounts & CommunicationsMr. Mark BaldygaVice President of & MarketingMore ExecutivesKey CompetitorsInMed PharmaceuticalsNASDAQ:INMCyclacel PharmaceuticalsNASDAQ:CYCCQualigen TherapeuticsNASDAQ:QLGNAllarity TherapeuticsNASDAQ:ALLRComera Life SciencesNASDAQ:CMRAView All Competitors BFRI Stock Analysis - Frequently Asked Questions Should I buy or sell Biofrontera stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biofrontera in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BFRI shares. View BFRI analyst ratings or view top-rated stocks. What is Biofrontera's stock price target for 2024? 1 equities research analysts have issued 1 year price objectives for Biofrontera's shares. Their BFRI share price targets range from $18.00 to $18.00. On average, they anticipate the company's stock price to reach $18.00 in the next twelve months. This suggests a possible upside of 1,328.6% from the stock's current price. View analysts price targets for BFRI or view top-rated stocks among Wall Street analysts. How have BFRI shares performed in 2024? Biofrontera's stock was trading at $2.77 on January 1st, 2024. Since then, BFRI shares have decreased by 54.5% and is now trading at $1.26. View the best growth stocks for 2024 here. Are investors shorting Biofrontera? Biofrontera saw a decrease in short interest during the month of February. As of February 29th, there was short interest totaling 110,300 shares, a decrease of 59.0% from the February 14th total of 269,100 shares. Based on an average trading volume of 728,100 shares, the short-interest ratio is currently 0.2 days. Approximately 10.7% of the company's stock are short sold. View Biofrontera's Short Interest. When is Biofrontera's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our BFRI earnings forecast. How were Biofrontera's earnings last quarter? Biofrontera Inc. (NASDAQ:BFRI) issued its quarterly earnings data on Friday, November, 10th. The company reported ($4.64) EPS for the quarter, missing the consensus estimate of ($4.23) by $0.41. The business had revenue of $8.90 million for the quarter, compared to analysts' expectations of $8.87 million. Biofrontera had a negative net margin of 78.65% and a negative trailing twelve-month return on equity of 192.05%. During the same quarter last year, the firm posted ($4.60) earnings per share. When did Biofrontera's stock split? Shares of Biofrontera reverse split on Wednesday, July 5th 2023. The 1-20 reverse split was announced on Wednesday, July 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What guidance has Biofrontera issued on next quarter's earnings? Biofrontera updated its FY 2023 earnings guidance on Tuesday, January, 30th. The company provided EPS guidance of for the period. The company issued revenue guidance of $33.8 million-$34.3 million, compared to the consensus revenue estimate of $35.9 million. When did Biofrontera IPO? (BFRI) raised $19 million in an IPO on Friday, October 29th 2021. The company issued 3,100,000 shares at $5.00-$7.00 per share. Roth Capital Partners and The Benchmark Company acted as the underwriters for the IPO. Who are Biofrontera's major shareholders? Biofrontera's stock is owned by a variety of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Biofrontera? Shares of BFRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BFRI) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biofrontera Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.